> top > docs > PMC:7536954 > annotations

PMC:7536954 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 223-227 Body_part denotes skin http://purl.org/sig/ont/fma/fma7163
T2 1444-1452 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T3 1575-1586 Body_part denotes thyroiditis http://purl.org/sig/ont/fma/fma9603
T4 2549-2560 Body_part denotes left axilla http://purl.org/sig/ont/fma/fma45303
T5 3029-3033 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T6 4519-4524 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T7 4539-4544 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T8 4588-4599 Body_part denotes lymphocytes http://purl.org/sig/ont/fma/fma62863
T9 4603-4621 Body_part denotes renal interstitium http://purl.org/sig/ont/fma/fma70983

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 223-227 Body_part denotes skin http://purl.obolibrary.org/obo/UBERON_0000014
T2 1997-2002 Body_part denotes Scale http://purl.obolibrary.org/obo/UBERON_0002542
T3 2554-2560 Body_part denotes axilla http://purl.obolibrary.org/obo/UBERON_0009472
T4 4539-4544 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 0-8 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 67-91 Disease denotes hidradenitis suppurativa http://purl.obolibrary.org/obo/MONDO_0006559
T3 67-79 Disease denotes hidradenitis http://purl.obolibrary.org/obo/MONDO_0002260
T4 96-124 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T5 105-124 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T6 157-181 Disease denotes Hidradenitis suppurativa http://purl.obolibrary.org/obo/MONDO_0006559
T7 183-185 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T8 210-235 Disease denotes inflammatory skin disease http://purl.obolibrary.org/obo/MONDO_0006501
T9 223-235 Disease denotes skin disease http://purl.obolibrary.org/obo/MONDO_0005093
T10 417-422 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T11 526-554 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T12 535-554 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T13 556-559 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T14 645-663 Disease denotes drug‐induced lupus http://purl.obolibrary.org/obo/MONDO_0016474
T15 658-663 Disease denotes lupus http://purl.obolibrary.org/obo/MONDO_0004670
T16 700-702 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T17 708-711 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T18 819-827 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T19 865-867 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T20 872-875 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T21 890-898 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T22 899-908 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T23 995-1003 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T24 1004-1013 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T25 1130-1138 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T26 1339-1342 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T27 1398-1407 Disease denotes nephritis http://purl.obolibrary.org/obo/MONDO_0001166
T28 1410-1421 Disease denotes myocarditis http://purl.obolibrary.org/obo/MONDO_0004496
T29 1427-1461 Disease denotes antiphospholipid antibody syndrome http://purl.obolibrary.org/obo/MONDO_0007140
T30 1564-1586 Disease denotes autoimmune thyroiditis http://purl.obolibrary.org/obo/MONDO_0005623|http://purl.obolibrary.org/obo/MONDO_0007699
T32 1575-1586 Disease denotes thyroiditis http://purl.obolibrary.org/obo/MONDO_0004126
T33 1588-1600 Disease denotes fibromyalgia http://purl.obolibrary.org/obo/MONDO_0005546
T34 1606-1618 Disease denotes osteoporosis http://purl.obolibrary.org/obo/MONDO_0005298
T35 1644-1646 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T36 1815-1817 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T37 2103-2106 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T38 2587-2589 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T39 2919-2922 Disease denotes flu http://purl.obolibrary.org/obo/MONDO_0005812
T40 2963-2971 Disease denotes diarrhea http://purl.obolibrary.org/obo/MONDO_0001673
T41 3002-3009 Disease denotes anosmia http://purl.obolibrary.org/obo/MONDO_0010528
T42 3011-3020 Disease denotes sinusitis http://purl.obolibrary.org/obo/MONDO_0005961
T43 3158-3166 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T44 3215-3219 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T45 3364-3372 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T46 3445-3447 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T47 3557-3565 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T48 3718-3720 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T49 3893-3895 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T50 3900-3903 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T51 3948-3956 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T52 4069-4071 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T53 4075-4078 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T54 4198-4200 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T55 4330-4345 Disease denotes lupus nephritis http://purl.obolibrary.org/obo/MONDO_0005556
T56 4330-4335 Disease denotes lupus http://purl.obolibrary.org/obo/MONDO_0004670
T57 4336-4345 Disease denotes nephritis http://purl.obolibrary.org/obo/MONDO_0001166
T58 4393-4402 Disease denotes psoriasis http://purl.obolibrary.org/obo/MONDO_0005083
T59 4716-4718 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T60 4765-4767 Disease denotes HS http://purl.obolibrary.org/obo/MONDO_0006559
T61 4798-4801 Disease denotes SLE http://purl.obolibrary.org/obo/MONDO_0007915
T62 4836-4840 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T63 4892-4901 Disease denotes psoriasis http://purl.obolibrary.org/obo/MONDO_0005083
T64 5033-5041 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T65 5042-5051 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T66 5081-5085 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T67 5092-5101 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T68 5197-5205 Disease denotes COVID‐19 http://purl.obolibrary.org/obo/MONDO_0100096
T69 5206-5215 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 190-191 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 223-227 http://purl.obolibrary.org/obo/UBERON_0000014 denotes skin
T3 223-227 http://purl.obolibrary.org/obo/UBERON_0001003 denotes skin
T4 223-227 http://purl.obolibrary.org/obo/UBERON_0002097 denotes skin
T5 223-227 http://purl.obolibrary.org/obo/UBERON_0002199 denotes skin
T6 223-227 http://www.ebi.ac.uk/efo/EFO_0000962 denotes skin
T7 417-444 http://purl.obolibrary.org/obo/PR_000000134 denotes tumor necrosis factor‐alpha
T8 446-449 http://purl.obolibrary.org/obo/PR_000000134 denotes TNF
T9 576-577 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T10 609-612 http://purl.obolibrary.org/obo/PR_000000134 denotes TNF
T11 732-737 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T12 935-940 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T13 1304-1305 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T14 1890-1891 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T15 1929-1930 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T16 2126-2134 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T17 2323-2328 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T18 2554-2560 http://www.ebi.ac.uk/efo/EFO_0001395 denotes axilla
T19 2641-2642 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T20 2673-2674 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T21 2917-2918 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T22 3494-3495 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 3496-3498 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T24 3795-3796 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T25 4117-4123 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T26 4135-4140 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T27 4366-4367 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T28 4497-4506 http://purl.obolibrary.org/obo/CLO_0001658 denotes activated
T29 4519-4524 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T30 4539-4544 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T31 4539-4544 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T32 4609-4621 http://purl.obolibrary.org/obo/UBERON_0005169 denotes interstitium
T33 4661-4662 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 183-185 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T2 308-319 Chemical denotes antibiotics http://purl.obolibrary.org/obo/CHEBI_33281
T3 321-330 Chemical denotes retinoids http://purl.obolibrary.org/obo/CHEBI_26537
T4 439-444 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T5 615-625 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T6 645-649 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T7 700-702 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T8 732-737 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T9 865-867 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T10 935-940 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T11 969-987 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T12 1062-1074 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T13 1093-1111 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T14 1495-1513 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T15 1518-1532 Chemical denotes salicylic acid http://purl.obolibrary.org/obo/CHEBI_16914
T16 1528-1532 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T17 1644-1646 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T18 1815-1817 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T19 1963-1965 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T20 2182-2200 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T21 2220-2228 Chemical denotes steroids http://purl.obolibrary.org/obo/CHEBI_35341
T22 2230-2250 Chemical denotes acetylsalicylic acid http://purl.obolibrary.org/obo/CHEBI_15365
T23 2246-2250 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T24 2256-2266 Chemical denotes pregabalin http://purl.obolibrary.org/obo/CHEBI_64356
T25 2323-2328 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T26 2587-2589 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T27 3301-3313 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T28 3332-3350 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T29 3445-3447 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T30 3718-3720 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T31 3749-3753 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T32 3893-3895 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T33 4032-4034 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T35 4069-4071 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T36 4135-4140 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T37 4198-4200 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T38 4573-4575 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T40 4716-4718 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T41 4765-4767 Chemical denotes HS http://purl.obolibrary.org/obo/CHEBI_74056
T42 5109-5127 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
4 47-54 Species denotes patient Tax:9606
5 0-8 Disease denotes COVID‐19 MESH:C000657245
6 67-91 Disease denotes hidradenitis suppurativa MESH:D017497
7 96-124 Disease denotes systemic lupus erythematosus MESH:D008180
29 417-444 Gene denotes tumor necrosis factor‐alpha Gene:7124
30 445-452 Gene denotes (TNF)‐α Gene:7124
31 609-614 Gene denotes TNF‐α Gene:7124
32 852-859 Species denotes patient Tax:9606
33 321-330 Chemical denotes retinoids MESH:D012176
34 381-391 Chemical denotes adalimumab MESH:D000068879
35 969-987 Chemical denotes hydroxychloroquine MESH:D006886
36 1062-1074 Chemical denotes azithromycin MESH:D017963
37 1093-1111 Chemical denotes hydroxychloroquine MESH:D006886
38 157-181 Disease denotes Hidradenitis suppurativa MESH:D017497
39 223-235 Disease denotes skin disease MESH:D012871
40 526-554 Disease denotes systemic lupus erythematosus MESH:D008180
41 556-559 Disease denotes SLE MESH:D008180
42 708-711 Disease denotes SLE MESH:D008180
43 819-827 Disease denotes COVID‐19 MESH:C000657245
44 872-875 Disease denotes SLE MESH:D008180
45 890-898 Disease denotes COVID‐19 MESH:C000657245
46 899-908 Disease denotes infection MESH:D007239
47 995-1003 Disease denotes COVID‐19 MESH:C000657245
48 1004-1013 Disease denotes infection MESH:D007239
49 1130-1138 Disease denotes COVID‐19 MESH:C000657245
70 1318-1323 Species denotes woman Tax:9606
71 1873-1880 Species denotes patient Tax:9606
72 1495-1513 Chemical denotes hydroxychloroquine MESH:D006886
73 1518-1532 Chemical denotes salicylic acid MESH:D020156
74 2182-2200 Chemical denotes hydroxychloroquine MESH:D006886
75 2220-2228 Chemical denotes steroids MESH:D013256
76 2230-2250 Chemical denotes acetylsalicylic acid MESH:D001241
77 2256-2266 Chemical denotes pregabalin MESH:D000069583
78 2276-2286 Chemical denotes adalimumab MESH:D000068879
79 2342-2353 Chemical denotes secukinumab MESH:C555450
80 1339-1342 Disease denotes SLE MESH:D008180
81 1398-1407 Disease denotes nephritis MESH:D009393
82 1410-1421 Disease denotes myocarditis MESH:D009205
83 1427-1461 Disease denotes antiphospholipid antibody syndrome MESH:D016736
84 1564-1586 Disease denotes autoimmune thyroiditis MESH:D013967
85 1588-1600 Disease denotes fibromyalgia MESH:D005356
86 1606-1618 Disease denotes osteoporosis MESH:D010024
87 1977-1981 Disease denotes pain MESH:D010146
88 2103-2106 Disease denotes SLE MESH:D008180
89 2114-2125 Disease denotes low‐disease MESH:D009800
92 2506-2517 Chemical denotes secukinumab MESH:C555450
93 2620-2631 Chemical denotes secukinumab MESH:C555450
116 2900-2907 Species denotes patient Tax:9606
117 3215-3225 Species denotes SARS‐CoV‐2 Tax:2697049
118 2695-2706 Chemical denotes secukinumab MESH:C555450
119 2875-2886 Chemical denotes secukinumab MESH:C555450
120 3268-3279 Chemical denotes Secukinumab MESH:C555450
121 3301-3313 Chemical denotes azithromycin MESH:D017963
122 3332-3350 Chemical denotes hydroxychloroquine MESH:D006886
123 3604-3615 Chemical denotes secukinumab MESH:C555450
124 2781-2785 Disease denotes pain MESH:D010146
125 2963-2971 Disease denotes diarrhea MESH:D003967
126 2993-3000 Disease denotes ageusia MESH:D000370
127 3002-3009 Disease denotes anosmia MESH:D000857
128 3011-3020 Disease denotes sinusitis MESH:D012852
129 3022-3027 Disease denotes fever MESH:D005334
130 3055-3063 Disease denotes asthenia MESH:D001247
131 3065-3072 Disease denotes myalgia MESH:D063806
132 3078-3088 Disease denotes arthralgia MESH:D018771
133 3098-3103 Disease denotes cough MESH:D003371
134 3107-3114 Disease denotes dyspnea MESH:D004417
135 3158-3166 Disease denotes COVID‐19 MESH:C000657245
136 3364-3372 Disease denotes COVID‐19 MESH:C000657245
137 3557-3565 Disease denotes COVID‐19 MESH:C000657245
163 4032-4038 Gene denotes IL‐17A Gene:3605
164 4573-4578 Gene denotes IL‐17 Gene:3605
165 3811-3818 Species denotes patient Tax:9606
166 3822-3829 Species denotes patient Tax:9606
167 4201-4209 Species denotes patients Tax:9606
168 4368-4375 Species denotes patient Tax:9606
169 4836-4846 Species denotes SARS‐Cov‐2 Tax:2697049
170 3917-3928 Chemical denotes secukinumab MESH:C555450
171 4088-4099 Chemical denotes Secukinumab MESH:C555450
172 4243-4254 Chemical denotes secukinumab MESH:C555450
173 4280-4290 Chemical denotes adalimumab MESH:D000068879
174 4646-4657 Chemical denotes secukinumab MESH:C555450
175 5109-5127 Chemical denotes hydroxychloroquine MESH:D006886
176 3900-3903 Disease denotes SLE MESH:D008180
177 3948-3956 Disease denotes COVID‐19 MESH:C000657245
178 4075-4078 Disease denotes SLE MESH:D008180
179 4319-4345 Disease denotes refractory lupus nephritis MESH:D008181
180 4393-4402 Disease denotes psoriasis MESH:D011565
181 4798-4801 Disease denotes SLE MESH:D008180
182 4892-4901 Disease denotes psoriasis MESH:D011565
183 5033-5041 Disease denotes COVID‐19 MESH:C000657245
184 5042-5051 Disease denotes infection MESH:D007239
185 5081-5101 Disease denotes SARS‐Cov‐2 infection MESH:C000657245
186 5197-5205 Disease denotes COVID‐19 MESH:C000657245
187 5206-5215 Disease denotes infection MESH:D007239

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 67-91 Phenotype denotes hidradenitis suppurativa http://purl.obolibrary.org/obo/HP_0040154
T2 96-124 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T3 157-181 Phenotype denotes Hidradenitis suppurativa http://purl.obolibrary.org/obo/HP_0040154
T4 183-185 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T5 210-235 Phenotype denotes inflammatory skin disease http://purl.obolibrary.org/obo/HP_0011123
T6 417-422 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T7 490-511 Phenotype denotes autoimmune conditions http://purl.obolibrary.org/obo/HP_0002960
T8 526-554 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T9 556-559 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T10 700-702 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T11 708-711 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T12 865-867 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T13 872-875 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T14 1339-1342 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T15 1398-1407 Phenotype denotes nephritis http://purl.obolibrary.org/obo/HP_0000123
T16 1410-1421 Phenotype denotes myocarditis http://purl.obolibrary.org/obo/HP_0012819
T17 1427-1452 Phenotype denotes antiphospholipid antibody http://purl.obolibrary.org/obo/HP_0003613
T18 1575-1586 Phenotype denotes thyroiditis http://purl.obolibrary.org/obo/HP_0100646
T19 1606-1618 Phenotype denotes osteoporosis http://purl.obolibrary.org/obo/HP_0000939
T20 1644-1646 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T21 1815-1817 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T22 1977-1981 Phenotype denotes pain http://purl.obolibrary.org/obo/HP_0012531
T23 2103-2106 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T24 2587-2589 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T25 2781-2785 Phenotype denotes pain http://purl.obolibrary.org/obo/HP_0012531
T26 2963-2971 Phenotype denotes diarrhea http://purl.obolibrary.org/obo/HP_0002014
T27 2993-3000 Phenotype denotes ageusia http://purl.obolibrary.org/obo/HP_0041051
T28 3002-3009 Phenotype denotes anosmia http://purl.obolibrary.org/obo/HP_0000458
T29 3011-3020 Phenotype denotes sinusitis http://purl.obolibrary.org/obo/HP_0000246
T30 3022-3027 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T31 3055-3063 Phenotype denotes asthenia http://purl.obolibrary.org/obo/HP_0025406
T32 3065-3072 Phenotype denotes myalgia http://purl.obolibrary.org/obo/HP_0003326
T33 3078-3088 Phenotype denotes arthralgia http://purl.obolibrary.org/obo/HP_0002829
T34 3098-3103 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T35 3107-3114 Phenotype denotes dyspnea http://purl.obolibrary.org/obo/HP_0002094
T36 3445-3447 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T37 3718-3720 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T38 3893-3895 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T39 3900-3903 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T40 4069-4071 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T41 4075-4078 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T42 4198-4200 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T43 4336-4345 Phenotype denotes nephritis http://purl.obolibrary.org/obo/HP_0000123
T44 4393-4402 Phenotype denotes psoriasis http://purl.obolibrary.org/obo/HP_0003765
T45 4716-4718 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T46 4765-4767 Phenotype denotes HS http://purl.obolibrary.org/obo/HP_0040154
T47 4798-4801 Phenotype denotes SLE http://purl.obolibrary.org/obo/HP_0002725
T48 4892-4901 Phenotype denotes psoriasis http://purl.obolibrary.org/obo/HP_0003765

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 423-431 http://purl.obolibrary.org/obo/GO_0070265 denotes necrosis
T2 423-431 http://purl.obolibrary.org/obo/GO_0019835 denotes necrosis
T3 423-431 http://purl.obolibrary.org/obo/GO_0008219 denotes necrosis
T4 423-431 http://purl.obolibrary.org/obo/GO_0001906 denotes necrosis

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-124 Sentence denotes COVID‐19 occurrence in one secukinumab‐treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus
T2 125-142 Sentence denotes CHIRICOZZI et al.
T3 144-156 Sentence denotes Dear Editor,
T4 157-459 Sentence denotes Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent.
T5 460-664 Sentence denotes Nevertheless, the presence of autoimmune conditions, particularly systemic lupus erythematosus (SLE), may represent a contraindication to the use of TNF‐α inhibitors due to the risk of drug‐induced lupus.
T6 665-837 Sentence denotes 1 Thus, the unique association of HS with SLE may require the off‐label use of immune‐targeted therapies that is cautiously monitored during the current COVID‐19 pandemic.
T7 838-988 Sentence denotes We report one patient with HS and SLE who developed COVID‐19 infection during treatment with off‐label secukinumab associated with hydroxychloroquine.
T8 989-1124 Sentence denotes Since COVID‐19 infection was diagnosed, secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks.
T9 1125-1303 Sentence denotes When COVID‐19‐related symptoms completely resolved, nasopharyngeal swab results were negative and secukinumab therapy was reintroduced after 8 weeks from the last administration.
T10 1304-1533 Sentence denotes A 28‐year‐old woman presented with SLE since the age of 13, with renal involvement (class III nephritis), myocarditis, and antiphospholipid antibody syndrome that was previously treated with hydroxychloroquine and salicylic acid.
T11 1534-1619 Sentence denotes Medical history also included autoimmune thyroiditis, fibromyalgia, and osteoporosis.
T12 1620-1684 Sentence denotes First manifestations of HS were reported at the age of 20 years.
T13 1685-1838 Sentence denotes Frequent flares (>2 episodes/months) occurred, and minimal clinical and ultrasonographic improvements were obtained with previous HS‐specific treatments.
T14 1839-1972 Sentence denotes At our observation (Fig. 1a), the patient reported a worsening of disease associated with a relevant disease burden (Hurley II; IHS4:
T15 1973-2009 Sentence denotes 12; pain‐Numeric Rating Scale [NRS]:
T16 2010-2025 Sentence denotes 7/10; itch‐NRS:
T17 2026-2042 Sentence denotes 3/10; HidraDisk:
T18 2043-2085 Sentence denotes 62; Dermatology Life Quality Index [DLQI]:
T19 2086-2090 Sentence denotes 15).
T20 2091-2267 Sentence denotes Concomitant SLE showed low‐disease activity with current maintenance therapy consisting of hydroxychloroquine (400 mg/day), oral steroids, acetylsalicylic acid, and pregabalin.
T21 2268-2473 Sentence denotes Because adalimumab was considered contraindicated, off‐label subcutaneous secukinumab injections at the dosage of 300 mg at weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing, were prescribed.
T22 2474-2526 Sentence denotes Figure 1 Clinical response to secukinumab therapy.
T23 2527-2676 Sentence denotes Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b).
T24 2677-2777 Sentence denotes After 20 weeks of secukinumab therapy (Fig. 1b), improvement of disease severity was observed (IHS4:
T25 2778-2790 Sentence denotes 8, pain‐NRS:
T26 2791-2810 Sentence denotes 0/10, and itch‐NRS:
T27 2811-2827 Sentence denotes 3/10; HidraDisk:
T28 2828-2857 Sentence denotes 13; DLQI:5; HiSCR: positive).
T29 2858-3115 Sentence denotes After 24weeks of secukinumab therapy, the patient referred a flu‐like episode initially characterized by diarrhea and then followed by ageusia, anosmia, sinusitis, fever (body temperature >38 °C), asthenia, myalgia, and arthralgia, without cough or dyspnea.
T30 3116-3267 Sentence denotes Nasopharyngeal swab was performed, as per COVID‐19 surveillance guidelines, resulting positive for SARS‐CoV‐2 on polymerase chain reaction (PCR) assay.
T31 3268-3363 Sentence denotes Secukinumab was interrupted, and azithromycin was combined with hydroxychloroquine for 2 weeks.
T32 3364-3463 Sentence denotes COVID‐19‐related symptoms completely resolved after 3 weeks with no worsening of HS manifestations.
T33 3464-3597 Sentence denotes Two nasopharyngeal swabs with a 48‐hour interval were performed after complete resolution of COVID‐19 symptoms and resulted negative.
T34 3598-3684 Sentence denotes Thus, secukinumab therapy was reintroduced after 8 weeks from the last administration.
T35 3685-3853 Sentence denotes Management of moderate to severe HS is challenging as no single drug is universally effective, thus requiring a personalized, patient‐by‐patient approach in most cases.
T36 3854-3966 Sentence denotes We reported an uncommon association of HS and SLE treated with secukinumab therapy during the COVID‐19 pandemic.
T37 3967-4079 Sentence denotes Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE.
T38 4080-4291 Sentence denotes 2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab.
T39 4292-4622 Sentence denotes 3 Successful treatment of refractory lupus nephritis with secukinumab in a patient complicated with psoriasis vulgaris was described, highlighting that clinical benefits were associated with reduction of activated T helper 17 cells in peripheral blood and reduced infiltration of IL‐17‐positive lymphocytes in renal interstitium.
T40 4623-4719 Sentence denotes 4 Thus, we considered secukinumab as a treatment option that resulted effective in treating HS.
T41 4720-5052 Sentence denotes Notwithstanding the overall effectiveness on HS and no detrimental effects on SLE, secukinumab was interrupted when SARS‐Cov‐2 was diagnosed in accordance with established psoriasis treatment guidelines and the latest recommendations issued by national and international scientific societies on the management of COVID‐19 infection.
T42 5053-5216 Sentence denotes Notably, our case developed SARS‐Cov‐2 infection during hydroxychloroquine therapy, which is under evaluation for the current management of the COVID‐19 infection.
T43 5217-5218 Sentence denotes 5